Tell us which new products made the most difference to your lab work and you’ll have the chance to win one of four $500 Amazon gift cards
Delivers enhanced galactosylation for improved protein quality, and antibody binding and function
First in a new range to advance identification and selection of cells with the highest productivity
Following last year’s success, we’re hosting our second annual event dedicated to celebrating our Seals of Quality program
Join this expert webinar to find out all you need to know about an innovative new method for tackling the first step of mAb purification
The VENTANA ROS1 (SP384) rabbit monoclonal primary antibody is designed to effectively identify elevated ROS1 protein expression
Discover an optimized, integrated workflow in our upcoming webinar for biopharmaceutical and biotech scientists
Complementary product portfolios will support and accelerate expansion into the pharmaceutical industry
New Rubella VLPs promise a reliable source of reagents for consistency in immunoassay development and manufacturing
Watch this on-demand webinar to learn how solutions from Sartorius are designed to increase the throughput of nanobody screening and discovery
ChLIA-based tests for detection of antibodies against Borrelia and Epstein-Barr virus now available on EUROIMMUN RA Analyzer 10 System
Discover a range of new technologies and applications for biopharmaceutical development in this special editorial feature
Find all the latest developments in antibody engineering and June’s top content from our drug discovery community
From rare pathogens to pandemic prevention, explore the latest techniques and technologies that are shaping today’s diagnosis and treatment of infectious diseases
This novel antibody labeling immunoassay for multiplex immune profiling aims to address one of the fastest growing, billion-dollar life science market sectors
Based on ESCAPE™ RNA sequencing technology, the latest proteogenomics assay is designed to characterize both RNA and protein expression levels across thousands of single CAR T cells
Avacta’s first Affimer clinical candidate is a potent PD-L1 antagonist under development for solid tumor indications as the basis of bispecific and combination therapies
High-throughput screening, antibody labeling, bispecific studies and more
SelectScience attended this year’s AAI IMMUNOLOGY conference to bring you the latest news and technology in the field
From lightning-fast labeling technology to real-time cytometry and high-throughput protein interaction analysis, find out what technologies are making the headlines in life sciences this month
As the global antibody market hits new heights, meet one scientist working to bridge the gap between biomarker discovery and antibody development with high-speed phage-display technology
